Artizan Biosciences
Pioneering precision therapeutics that neutralize microbial triggers to restore intestinal health to treat diseases.
| USD | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 101 % | - |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Artizan Biosciences, Inc. is a biotechnology company focused on developing microbiome-based therapies to treat chronic diseases. The company leverages cutting-edge research from Yale Immunobiology faculty members to create precision medicine solutions that target the root causes of various chronic conditions. Artizan Biosciences operates in the biopharmaceutical market, primarily serving healthcare providers and patients who suffer from chronic diseases. The business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary therapies. Revenue is generated through partnerships, grants, and future sales of approved treatments. The company aims to revolutionize the treatment landscape by offering targeted, effective, and personalized medical solutions.
Keywords: microbiome, chronic diseases, precision medicine, biotechnology, immunobiology, healthcare, biopharmaceutical, research, development, therapies.